Among the other tumors, TXNIP expression is down‐regulated in chronic myeloid leukemia (CML) in response to activated BCR‐ABL fusion protein that stimulates glucose metabolism, mainly by increasing glucose transporter exposure at the plasma membrane. This evidence concerns the gene TXNIP and chronic myelogenous leukemia, BCR-ABL1 positive.